Low rather than high interleukin-6 levels are associated with immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
In cancer patients treated with ICIs, low rather than high post-ICI IL-6 levels, female sex and dual ICI therapy are independent risk factors for irAEs.
Authors
- Inés Pérez-Francisco
- Iñaki Elejalde
- M. Martínez Kareaga (ORCID: https://orcid.org/0000-0002-2599-5791)
- Manuela Moro Cabero (ORCID: https://orcid.org/0000-0001-5301-1924)
- Virginia Arrazubi (ORCID: https://orcid.org/0000-0002-1431-2780)
- Berta Ibáñez (ORCID: https://orcid.org/0000-0002-7797-4845)
- Ibone de Elejoste
- Íñigo Les (ORCID: https://orcid.org/0000-0002-2769-0676)
- Ana Campillo-Calatayud (ORCID: https://orcid.org/0000-0003-0017-1048)
- Amaia Moreno
- David de Haedo
Institutions
- Servicio Navarro de Salud (ES)
- Biogipuzkoa Health Research Institute (ES)
- Red de Investigación en Actividades Preventivas y Promoción de la Salud (ES)
- Hospital Universitario Araba (ES)
- Navarre Institute of Health Research (ES)
- Hospital de Galdakao (ES)
- Navarrabiomed (ES)
- Donostiako Unibertsitate Ospitalea (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Instituto de Investigación Sanitaria La Fe (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1677778
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00